

# Enhanced Drug List Updates

July 2018

TRADE NAME (generic name) or generic name	Brand/Generic Product	Description of Change
BELSOMRA (suvorexant tab 10 mg)	Brand	Addition, Preferred Status
BELSOMRA (suvorexant tab 15 mg)	Brand	Addition, Preferred Status
BELSOMRA (suvorexant tab 20 mg)	Brand	Addition, Preferred Status
BELSOMRA (suvorexant tab 5 mg)	Brand	Addition, Preferred Status
EXJADE (deferasirox tab for oral susp 125 mg)	Brand	Addition, Preferred Status
EXJADE (deferasirox tab for oral susp 250 mg)	Brand	Addition, Preferred Status
EXJADE (deferasirox tab for oral susp 500 mg)	Brand	Addition, Preferred Status
GLYXAMBI (empagliflozin-linagliptin tab 10-5 mg)	Brand	Addition, Preferred Status
GLYXAMBI (empagliflozin-linagliptin tab 25-5 mg)	Brand	Addition, Preferred Status
HEMLIBRA (emicizumab-kxwh subcutaneous soln 105 mg/0.7ml (150 mg/ml))	Brand	Addition, Preferred Status
HEMLIBRA (emicizumab-kxwh subcutaneous soln 150 mg/ml)	Brand	Addition, Preferred Status
HEMLIBRA (emicizumab-kxwh subcutaneous soln 30 mg/ml)	Brand	Addition, Preferred Status
HEMLIBRA (emicizumab-kxwh subcutaneous soln 60 mg/0.4ml (150 mg/ml))	Brand	Addition, Preferred Status
JADENU (deferasirox tab 180 mg)	Brand	Addition, Preferred Status
JADENU (deferasirox tab 360 mg)	Brand	Addition, Preferred Status
JADENU (deferasirox tab 90 mg)	Brand	Addition, Preferred Status
JANUVIA (sitagliptin phosphate tab 25 mg (base equiv))	Brand	Addition, Preferred Status
JANUVIA (sitagliptin phosphate tab 50 mg (base equiv))	Brand	Addition, Preferred Status
JANUVIA (sitagliptin phosphate tab 100 mg (base equiv))	Brand	Addition, Preferred Status
KOMBIGLYZE XR (saxagliptin-metformin hcl tab er 24hr 2.5-1000 mg)	Brand	Addition, Preferred Status
KOMBIGLYZE XR (saxagliptin-metformin hcl tab er 24hr 5-500 mg)	Brand	Addition, Preferred Status
KOMBIGLYZE XR (saxagliptin-metformin hcl tab er 24hr 5-1000 mg)	Brand	Addition, Preferred Status
ONGLYZA (saxagliptin hcl tab 2.5 mg (base equiv))	Brand	Addition, Preferred Status
ONGLYZA (saxagliptin hcl tab 5 mg (base equiv))	Brand	Addition, Preferred Status
OZEMPIC (semaglutide soln pen-inj 0.25 or 0.5 mg/dose (2 mg/1.5ml))	Brand	Addition, Preferred Status
OZEMPIC (semaglutide soln pen-inj 1 mg/dose (2 mg/1.5ml))	Brand	Addition, Preferred Status
REBINYN (coagulation factor ix recomb glycopegylated for inj 1000 unt)	Brand	Addition, Preferred Status
REBINYN (coagulation factor ix recomb glycopegylated for inj 2000 unt)	Brand	Addition, Preferred Status
REBINYN (coagulation factor ix recomb glycopegylated for inj 500 unt)	Brand	Addition, Preferred Status
TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol aepb 100-62.5-25 mcg/inh)	Brand	Addition, Preferred Status
ZENPEP (pancrelipase (lip-prot-amyl) dr cap 25000-79000-105000 unit)	Brand	Addition, Preferred Status
ZENPEP (pancrelipase (lip-prot-amyl) dr cap 5000-17000-24000 unit)	Brand	Addition, Preferred Status

Blue Cross and Blue Shield of Illinois (BCBSIL), Blue Cross and Blue Shield of Montana (BCBSMT), Blue Cross and Blue Shield of New Mexico (BCBSNM), Blue Cross and Blue Shield of Oklahoma (BCBSOK), and Blue Cross and Blue Shield of Texas (BCBSTX) are Divisions of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association. BCBSIL, BCBSMT, BCBSNM, BCBSOK, and BCBSTX contract with Prime Therapeutics to provide pharmacy benefit management and related other services. BCBSIL, BCBSMT, BCBSNM, BCBSOK, and BCBSTX, as well as several independent Blue Cross and Blue Shield Plans, have an ownership interest in Prime Therapeutics LLC.